LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regeneron Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

492.82 2.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

491.37

Max

495.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

-109M

809M

Verkäufe

-761M

3B

KGV

Branchendurchschnitt

12.47

51.198

EPS

8.22

Dividendenrendite

0.72

Gewinnspanne

26.701

Angestellte

15,158

EBITDA

-54M

1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+46.86% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.72%

2.40%

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-22B

53B

Vorheriger Eröffnungskurs

490.69

Vorheriger Schlusskurs

492.82

Nachrichtenstimmung

By Acuity

37%

63%

117 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Regeneron Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Mai 2025, 11:55 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million

29. Apr. 2025, 11:07 UTC

Ergebnisse

Regeneron 1Q Profit Rises, Revenue Falls; FY25 CapEx Target Trimmed

4. Feb. 2025, 12:13 UTC

Ergebnisse

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

5. Juni 2025, 01:41 UTC

Akquisitionen, Fusionen, Übernahmen

23andMe's Former CEO Pushes Purchase Price Nearly $50 Million Higher -- WSJ

30. Mai 2025, 08:58 UTC

Heiße Aktien

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30. Mai 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

19. Mai 2025, 17:52 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19. Mai 2025, 16:13 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron Is Buying 23andMe. The Deal Is a Head Scratcher. -- Barrons.com

19. Mai 2025, 14:42 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- 2nd Update

19. Mai 2025, 13:33 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million -- Update

19. Mai 2025, 11:10 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron: To Ensure Compliance With 23andMe Consumer Privacy Policies, Applicable Laws on Customer Data >REGN

19. Mai 2025, 11:10 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron: 23andMe Transaction Expected to Close in 3Q >REGN

19. Mai 2025, 11:09 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron: To Continue All 23andMe Consumer Genome Services Uninterrupted >REGN

19. Mai 2025, 11:08 UTC

Akquisitionen, Fusionen, Übernahmen

Regeneron: Named Successful Bidder in Bankruptcy Auction for Substantially All Assets of 23andMe >REGN

29. Apr. 2025, 18:04 UTC

Market Talk
Ergebnisse

Regeneron Sinks As Sales Of Key Eye Medication Tumble -- Market Talk

29. Apr. 2025, 14:39 UTC

Market Talk
Ergebnisse

Regeneron's Eylea Setback Drags Stock as Investor Frustrations Mount -- Market Talk

29. Apr. 2025, 14:29 UTC

Ergebnisse

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29. Apr. 2025, 13:11 UTC

Ergebnisse

Regeneron Stock Plummets After Earnings Miss -- Barrons.com

29. Apr. 2025, 10:32 UTC

Ergebnisse

Regeneron Pharma Cuts 2025 CapEx to $850M-$950M >REGN

29. Apr. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 1Q Rev $3.03B >REGN

29. Apr. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 1Q Net $808.7M >REGN

29. Apr. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 1Q EPS $7.27 >REGN

29. Apr. 2025, 10:30 UTC

Ergebnisse

Regeneron Pharma 1Q Adj EPS $8.22 >REGN

22. Apr. 2025, 10:51 UTC

Top News

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28. Feb. 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4. Feb. 2025, 11:58 UTC

Ergebnisse

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4. Feb. 2025, 11:37 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4. Feb. 2025, 11:37 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4. Feb. 2025, 11:36 UTC

Ergebnisse

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4. Feb. 2025, 11:35 UTC

Ergebnisse

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

Peer-Vergleich

Kursveränderung

Regeneron Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

46.86% Vorteil

12-Monats-Prognose

Durchschnitt 724.35 USD  46.86%

Hoch 900 USD

Tief 535 USD

Basierend auf 23 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Regeneron Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

23 ratings

17

Buy

5

Halten

1

Sell

Technischer Score

By Trading Central

542.44 / 599.76Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Strong Bullish Evidence

Langfristig

Weak Bearish Evidence

Stimmung

By Acuity

117 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.